ASX Health Stocks: BOD to acquire Aqua Phase on positive data; Bionomics set to delist

Bod Science to go ahead with Aqua Phase acquisition after study results
Osteopore to ramp up China business after $10m partnership deal
Bionomics to delist from the ASX

Bod Science’s study supports acquisition of Aqua Phase

Cannabis focused biotech Bod Science (ASX:BOD) rose 15% this morning after announcing the completion of its pharmacokinetic (PK) studies evaluating the bioavailability of cannabidiol (CBD) in capillary blood samples.

Successful completion of a PK study is the final condition for the acquisition of the Aqua Phase delivery technology.

BOD is in the process of acquiring Aqua Phase, a potential breakthrough technology that could radically improve the bioavailability of CBD medications.

The results today showed that total CBD availability (as measured by area under the curve, AUC) using Aqua Phase CBD was statistically significantly greater than CBD oil by 311%.

The maximum concentration (Cmax) was also statistically significantly higher at 277% (3.8 times) more than CBD oil.

The PK Study has now satisfied the condition associated with the acquisition of Aqua Phase, which required improved bioavailability of greater than 30%.

BOD says the commercialisation of Aqua Phase provides multiple opportunities to expand Bod’s business.

“We are at the precipice of an exciting chapter where we will be talking to potential collaborators across vast industries on the value of Aqua Phase its application and the solution it can provide,” said Bod Science CEO, Jo Patterson.

Now read: How Bod Science pulled ahead in the race for Australia’s first over-the-counter CBD

Osteopore to accelerate China business

Regenerative bone specialist Osteopore (ASX:OSX) has signed a non-binding term sheet with CellHeal which will commit $10m to accelerate commercialisation in China.

Under the deal, CellHeal will set up manufacturing facilities, attain regulatory approvals and commercialise select Osteopore regenerative medicine technology applications in China.

The term sheet includes a proposed royalty per product of 10-20% for Osteopore as a percentage of net sales.

Osteopore said this partnership marks a transformational opportunity and will pave the way for greater market penetration and visibility in China for Osteopore’s products

The regenerative medicine market in China was reported to be $5.9 billion in 2021, and is expected to be worth $19.2 billion by 2030.

Bionomics to delist from the ASX

Bionomics (ASX:BNO) will say goodbye to the ASX, as it announced a voluntary delisting.

Bionomics said its Board has ultimately determined that the costs and administrative burden of remaining listed on ASX outweigh any benefits of a continued listing.

Following the delisting, the company said it will maintain listing on the Nasdaq.

Meanwhile, health tech company OneView (ASX:ONE) dropped over 20% this morning after undertaking and receiving placement commitments for approximately $20m.

The placement will result in the dilutive issue of approximately 111 million new CDIs at $0.18 per CDI.